ACADIA PHARMACEUTICALS INC
ACADIA PHARMACEUTICALS INC (ACAD): 20 pipeline candidates · 8 upcoming catalysts · ~11 mo cash runway · 48 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
10.8 months
D/E 0.29 · 1% dilution
Lead: Approved
20 candidates
8 upcoming, next in ~196d
0 buys · 15 sells (180d)
A transparent, data-derived signal for ACADIA PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.7B
Cash
$282.2M
Quarterly Burn
$247.9M
Runway
10.8 mo
Revenue
$268.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (20 candidates)
| Drug | Phase |
|---|---|
| acetazolamide | Approved |
| ACP-044 Dose A | Phase 2 |
| ACP-044 Dose B | Phase 2 |
| acp-103 | Phase 2 |
| ACP-104 | Phase 2 |
| ACP-204 | Phase 2 |
| ACP-211 | Phase 2 |
| Active drug | Phase 2 |
| bupropion | Approved |
| Carbetocin | Phase 3 |
Showing 10 of 20 candidates. Sign up for full pipeline.
Upcoming Catalysts (8)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
342
Total value held
$3.80B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 42,896,690 | $954.9M |
| blackrock, inc. | 21,550,921 | $479.7M |
| vanguard capital management llc | 11,322,800 | $252.0M |
| vanguard portfolio management llc | 8,671,645 | $193.0M |
| state street corp | 8,332,771 | $185.5M |
| rtw investments, lp | 7,144,524 | $159.0M |
| geode capital management, llc | 3,464,689 | $77.1M |
| first trust advisors lp | 3,343,868 | $74.4M |
| dimensional fund advisors lp | 3,155,160 | $70.2M |
| palo alto investors lp | 2,872,695 | $63.9M |
Showing top 10 of 342 institutional holders of ACADIA PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ACADIA PHARMACEUTICALS INC's pipeline?
ACADIA PHARMACEUTICALS INC (ACAD) has 20 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ACADIA PHARMACEUTICALS INC's lead drug candidate?
ACADIA PHARMACEUTICALS INC's most advanced tracked candidate is acetazolamide (Approved) for INDICATIONS AND USAGE: For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide extended-release capsules are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent..
What is ACADIA PHARMACEUTICALS INC's next catalyst?
ACADIA PHARMACEUTICALS INC's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: remlifanserin" — expected December 31, 2026.
What is ACADIA PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ACADIA PHARMACEUTICALS INC has approximately 10.8 months of cash runway.
What is ACADIA PHARMACEUTICALS INC's market capitalization?
ACADIA PHARMACEUTICALS INC's market capitalization is approximately $3.7B.
Get the full picture on ACADIA PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.